​​ABOUT 9th_HTIF
> ATTENDEES
> INVESTORS
​> PRESENTERS
> EXHIBITORS
> SPONSORS
> SUPPORTERS

20-minute Presenters

Mirai Medical Ltd.

Mirai Medical is an Irish medical device company focussed on the improved treatment of gastrointestinal cancers. Mirai has developed an innovative endoscopic solution to successfully treat cancers without harming healthy tissue. Our technology is delivered within minutes as a daycase procedure reducing the cost and hospitalisation time for the patient.

The ePORE and EndoVE platform developed by Mirai Medical is CE approved with FDA engagement underway. Mirai is currently developing additional endoscopic devices to allow all cases of gastrointestinal cancer from premalignant to advanced to be successfully treated.

www.mirai-medical.com/

Omixon Biocomputing Kft.

Omixon is a 60-person, revenue-generating, VC-backed transplantation diagnostics company with customers in 25 countries, headquartered in Budapest, Hungary, subsidiaries in Cambrdge, MA and in the Netherlands. Omixon’s mission is to improve transplant outcomes. Omixon was the first to introduce high resolution histocompatibility testing on Illumina next-generation sequencing platform with its NanoTYPE HLA genotyping product. In May 2022, an Omixon customer made history with the first sub-5-hour, high-resolution, emergency histocompatibility testing with transformative potential for sensitised patients on the waiting list. Omixon is seeking $10M investment to aggressively enter the market with NanoTYPE and to develop HoloGRAFT, a proprietary, best-in-class cfDNA assay for post-transplant monitoring, at dramatically lower cost-of-goods than competition, in a CMS-reimbursed, multi-billion-dollar, blue-ocean market.

www.omixon.com

PIXIUM VISION
[EURONEXT : ALPIX]

PIXIUM VISION harnesses rapid advances in visual processing, micro-electronics, opto-electronics, neurobiology, and intelligent software algorithms to develop Bionic Vision Systems utilizing its competencies in machine brain interface and artificial intelligence.

These Bionic Vision Systems are aimed at compensating for profound vision loss and improving the independence, mobility and quality of life for patients suffering with retinal degenerative diseases.

www.pixium-vision.com

10-minute Presenters

Annaida Technologies SA

Annaida is a spinoff from EPFL in Lausanne. During his PhD, cofounder and now CTO Marco Grisi developed a groundbreaking non-invasive sensor technology. Realizing its potential, he joined forces with cofounder and now CEO Gora Conley to create the company and bring the technology to real world applications.

​The first core application is in fertility treatment through IVF, where a non-invasive screening tool to identify the most viable embryos is highly sought after.

Collaborations with leading clinics, an expert team and an advisory board including a Nobel Prize are the winning ingredients of Annaida.

www.annaida.ch/

AOT AG

We Laser Bone

We will improve orthopedic surgeries with safety, better bone healing, intra- and post-operativ bone stability and high precision surgery.

We are a surgical robotics company located in Basel, Switzerland. After more than a decade of R&D, our autonomous CARLO® Laser Robot is CE approved for use in operating rooms across Europe. With a comprehensive record of pre-clinical testing, and over 100 successful clinical cases, CARLO® has demonstrated its readiness and unique value.

Contact-free orthopedic surgery, robotic laser precision, functional cut geometries and healing advantages, all in an easy to adopt, user-friendly system. Our highly differentiated technological innovations are protected by more than 10 patent families globally.

www.aot.swiss

Centogene N.V.
[​Nasdaq: CNTG]

CENTOGENE (Nasdaq: CNTG) is transforming real-world clinical, genetic, and multiomic data to enable better health outcomes for patients with rare and neurodegenerative diseases. For over 15 years, CENTOGENE has been providing diagnostic insights to patients with genetic diseases through our network of nearly 30,000 active physicians. CENTOGENE now believes its Biodatabank is the world’s largest real-world data repository of corresponding patients from more than 120 countries. Simplified logistics solutions, including CentoCard® for sending biosamples, and our ISO, CAP, & CLIA certified state-of-the-art multiomic reference labs offer patients rapid and reliable diagnoses to support the identification and personalization of their treatments. Ultimately, offering the best treatment for patients involves developing new or better therapies. We are de-risking orphan drug discovery and development by partnering with more than 30 biopharma in target & drug screening, clinical development, market access and expansion. CENTOGENE engages in biodata partnerships with our Biodata Licenses and Insight Reports.
​
www.centogene.com/

DataHow AG

DataHow is a spin-off company from ETH Zurich focusing on industry 4.0 software for the pharma and chemical industry.

​DataHow’s model-based software solutions are used to support decision taking and automation for manufacturing of complex products, e.g. biopharmaceutical drugs.

The company's value proposition is to substantially reduce ressources in process development and risks in manufacturing.

Since creation in 2017, more than 10 of the largest 20 big pharma companies are using DataHow's technology. The DataHow team of 45 team members operates on three continents. By 2026 DataHow targets to be a central service and product provider of industry 4.0 technology for biopharma manufacturing.

www.datahow.ch

Grapheal SAS

Grapheal is a Medtech/Deeptech Spin-off from CNRS-Grenoble, France, producing smartphone-connected wearables for precision medicine. Grapheal brings connectivity to biosensing by designing embedded biosensors and flexible wearables powered by & coupled to RFID. Grapheal's devices aim to provide field diagnostics and remote patient biomarker monitoring solutions, focusing on pathogens detection and on wound care monitoring.

https://www.grapheal.com

Laser Team Medical ltd

Laser Team Medical (LTM) develops medical laser systems using its own laser cavity. The company first developed a laser system that enables treatment for people for whom laser treatment was previously unsuitable. It can treat people with darker skin as well as people who use the laser technology today. The LTM laser is more accurate than current medical lasers, can penetrate deeper, and does not heat the surrounding area, so it does not cause pain. The LTM system can treat scars, rejuvenate skin, be used for surgical applications, and more.

lasertm.com/

lifespin GmbH

Lifespin is building a smart Health diagnostic platform that combines biology, Deep Data, artificial intelligence and cloud technology to enable digital metabolic insights for: precision diagnostics and personalized disease management; precision drug monitoring for pharmaceutical, research and clinical settings; and precision nutrition for diabetes, obesity, diet and lifestyle interventions. Lifespin products are software algorithms scalable via the cloud as software-as-a-service (SaaS).

lifespin.health/

MedTrace Pharma A/S

MedTrace Pharma A/S (Denmark) is working to eliminate diagnostic uncertainty by innovating medical imaging to help health care professionals diagnose patients better and faster.

Specifically, MedTrace is marking the gold standard perfusion tracer (15O-water PET) practically availably for clinical use, hence increasing accuracy of functional imagining of heart patients by 50% while increasing efficiency in patient turnaround by a factor of 4 - compared to today's clinical work horse; Cardiac SPECT scans.

Growing rapidly and backed by strong investors such as Swisscanto Private Equity, the Danish pension fund ATP and the European Innovation Council.

Seeking investors to join a strong syndicate of current key shareholders to finalize phase III clinical trial and go-to-market in Europe and the US.

Specialties
O15 water, Nuclear Medicine, Radioactive water, Medical Devices, radiopharmaceutical, myocardial perfusion, molecular imaging, PET/CT, Cardiac Imaging, Perfusion Imaging, Cardiac PET, and Medical Imaging

www.medtrace.dk/

NeoPrediX AG

NeoPrediX develops decision support tools with maternal, neonatal and perinatal screening platforms to evaluate, optimize and personalize medical strategies in pediatrics. We utilize intelligent algorithms and digital health solutions for neonatal and perinatal care based on deep medical data and science, developed by experienced scientists, pediatricians, and neonatologists.

www.neopredix.com/de/

OmnySense, Ltd.

OmnySense is a digital-health company which is poised to revolutionize the way in which telehealth is implemented and managed in the mass market.

OmnySense is the only company transforming the simplest and most familiar medical device - the thermometer - into the basis of a multi-parameter, connected health-tracking solution.

The company has developed devices and algorithms which can enable detailed health tracking of patients at home using a numbers-based approach; while minimizing the requirement for physician involvement.

OmnySense will pursue a SaaS type subscription model in collaboration with a range of potential marketing partners, including pharmacy chains and omny-channel healthcare providers.

​www.omnysense.com

Pacertool AS

Pacertool is addressing a large unmet need for the more than 200'000 heart failure patients in need of pacing every year: optimal patient selection and optimized lead placement. Currently, 30-40% of heart failure patients who get a bi-ventricular pacemaker ("CRT") implanted have limited effect of the therapy. Pacertool is solving this problem with the PaCRTool system: a proprietary platform which helps physicians to select patients and to optimize lead placement including avoiding scar tissue in ischemic patients.

The company has established proof-of-principle data in 45 heart failure patients with more than 2 years follow-up. The data indicate differentiation between responders and non-responders. Pacertool is implementing a 510(k) strategy in the US and is initiating the First-in-Patient clinical trial in Europe from 2024.

​pacertool.com/

PreciHealth SA

PreciHealth is a Swiss private medtech & i-health company working on disruptive blood sampling devices for remote patients diagnosis and self-injections. Precihealth develops also a very unique AI based companion application that authenticates, guides the user, verifies the process allowing certification for blood sampling sent to the Labs.

3 out of the top players in the field, are recognizing PreciHealth solution for remote diagnosis as the most appealing and are discussing significant commercial collaborations.

We are raising our series A financing round of CHF/EUR/$ 12.5m. We truly believe this point of time in the lifetime of the company is a unique opportunity for investors to join before the next valuation inflexion point.

www.precihealth.com/

Pristine Surgical LLC

Pristine Surgical is a medical device company with a mission to simplify endoscopy. The company combines single-use endoscopes with cloud-based software to make minimally invasive visualization more efficient, consistent, and safe. Pristine Surgical offers a unique subscription business model with transparent pricing and automated inventory management, delivering improved workflow and reduced costs to the endoscopy suite.

www.pristinesurgical.com/

Rea Diagnostics SA

Rea Diagnostics is a Swiss, Lausanne-based, MedTech startup and a spin-off of the École polytechnique fédérale de Lausanne (EPFL).

We are working on women healthcare diagnostics. Our first product is a self-test to detect the risk of preterm birth from home. Our test is coupled to an app to offer a digital health service for remote monitoring for the risk of preterm birth. ​

readiagnostics.com

Spindiag GmbH

Spindiag provides solutions to keep patients and staff safe from infections by providing safe, simple and efficient diagnostics for infectious diseases. Our point-of-care PCR solution is uparalleled in its ease-of-use and sensitivity. Our customers appreciate the efficient and economical patient pathways in their hospital enabled by our system. We currently offer and expanding test menu for SARS-CoV-2, MRSA and a combined RESPI-test for Influenza A/B, RSV and SARS-CoV-2. ​

www.spindiag.de/

European Health Techs Presented by EIT Health e.V.

​Acorai AB

Acorai is developing a medical device to improve heart failure (HF) patient management through non-invasive intracardiac pressure monitoring. Our device, The Acorai Heart Monitor, is one of its kind and can non-invasively monitor the intracardiac pressures (the most important vital signs when it comes to managing HF patients). Our patented and clinically validated solution is built on novel machine learning insights into pressure and flow dynamics in acoustic, vibratory and waveform data.
Most importantly, we have a unique value proposition that appeals to both healthcare professionals and payors which further strengthens our potential.

VISION: To ensure optimal care for HF patients globally.
MISSION: To create a product that changes people’s lives. To be part of the transformation of the medical industry towards non-invasive, cost-effective, and more inclusive technologies, thereby increasing the reach of care.

acorai.com/

Aortyx SL

Aortyx is a pioneer company developing the next generation of vascular implants. With aortic dissection as first indication to demonstrate the power of the platform, the company is developing a family of biomimetic, bioresorbable endovascular patches that are deployed via a specialized aortic catheter. The patches are designed to adhere to the vessel wall, and to promote natural repair of the aorta and biointegration within the native tissue. These features will allow safer surgeries, with lower mortality, secondary effects and reintervention rates and will increase the eligibility of currently unfit patients. Aortyx' pipeline of products uses the patch + catheter system as a platform to locally deliver drugs using advanced nanomaterials, for a combined market of up to 3 billion dollars.

aortyx.com

DigiSurge

Digisurge is a French startup developing a robotic platform dedicated to structural heart repair and reconstruction.

This end-to-end solution targets a set of procedures that will replace open-heart or minimally invasive operations, on aortic, pulmonary and mitral valves.

The DigiSurge robotic platform is a cardiologist-centric solution, that aims to provide quicker, safer, repeatable, and cost-effective “beating-heart” procedures, with an unprecedent ergonomics thanks to features like IA based real-time image guided navigation, augmented dexterity, real-time echograph / RMI image fusion, augmented reality.

The first targeted application is the robotization of the transcatheter transfemoral mitral valve annuloplasty which is only available today on open-heart procedure, making only 2,5% patients undergoing surgical treatment. The US market alone represents a potential of 600K patients.

This program has been awarded by an international jury to benefits from a grant that gives Digisurge a 17M€ financing, with the collaboration of a consortium of 8 top-level French Research Laboratories along with a lead hospital in cardiac surgery (HCL).

www.digisurge.fr

Epios SA

Epios: Brainwaves unlocked:

Epios is a clinical stage company providing precision care for brain disorders using actionable insights derived from our unique long-term brain neuro-sensing and therapeutics modality. As you can only manage what you can measure we are launching first a minimally invasive 24/7 electroencephalographic recording system for use outside the clinic.
Simply put, we propose a “smart watch” for the brain.

The first use case will be pre-surgical planning and treatment optimization to improve outcomes and cost of care for people living with epilepsy. Our platform technology will then be deployed in other indications (sleep disorders, stroke ...) moving also from neuro-sensing only to real-time intervention and finally therapeutics.

epios.ch

InCephalo

InCephlao is a preclinical biotech company focusing on brain cancer disease. Its proprietary compartment-locked technology allows the creation of tailor-made molecules for the local application of drugs against brain tumours. Its primary asset has received EMA orphan designation and is envisioned to go into the clinic by 2024.

incephalo.com

​MiMARK Diagnostics, S.L.

MiMARK is a Women’s’ health, Women-led spin-off that aims to revolutionize gynecological diagnostics. The mission of the company is to positively impact the lives of women suffering from gynecological conditions. MiMARK aims to develop new IVD products for improving women’s health based on its deep understanding of gynecological fluids.

The company will leverage this knowledge to develop its first test WomEC, a diagnostic test for EC and complementary solutions to WomEC (WomEC Px a prognostic test, and WomEC Sc a screening test) but also to tackle other gynecological malignancies affecting the lower gynecological tract. Our core business is mainly targeting the development stages of innovative solutions for Womens’ health following quality and regulatory requirements, including prototype development, clinical validation and utility, and IP improvement. In addition, the company will support its licensees in the areas of market access and reimbursement, networking and building strong KOL support.

MiMARK is a spin-off from the Vall Hebron Institute of Research (VHIR) founded in January 2021. The co-founders are three experienced professionals with highly complementary profiles. Marina Rigau, the CEO, comes from a scientific background with significant experience in science management. Eva Colás, the CSO, has dedicated all her scientific career to understanding the gynecological fluid. Antonio Gil, the CMO, is the Head of Gynecology Services at the Vall Hebron Hospital and is a well-respected clinician at the national and international levels.

MiMARK was the winning company in the EIT Health Wild Card competition targeted at Women’s Health in 2020 and was awarded with 1.5M€ that is being provided according to milestone achievements from April 2021 to December 2022.

www.mimark.es

Reactive Robotics GmbH

Reactive Robotics has developed the world’s first AI-driven robotic assistance system for intensive care. Our smart robot for Intensive Care Unit (ICU) patient rehabilitation have the potential to reduce cost per ICU patient by over 8k USD via early mobilization therapy. Clinical studies with >1.000 patients show that mobilization therapy in ICU accelerates recovery of ICU patients, who can leave the ICU over 20% (~1,4 days) faster. However, critical staff shortages, aggravated due to COVID-19, have dramatically reduced hospital’s capabilities to deliver therapy effectively. Besides faster recovery, the use of our robot can reduce human resource by up to 3 nurses per therapy.

www.reactive-robotics.com

Sensius BV

Sensius changes the way we treat cancer. By adding thermotherapy to radio- or chemotherapy we create a new balance between survivorship and quality of life by improving both. Sensius is a scale-up medical device company with strong endorsements from key opinion leaders.

sensiusthermotherapy.com

VIRTUAL PRESENTERS:

20-minute presenters

eTheRNA

eTheRNA has developed a proprietary and integrated set of platform technologies that are overcoming the challenges facing the development of next generation mRNA therapeutics. Our platforms include mRNA construct design and optimization, proprietary lipid nanoparticles (LNP) and formulations, and in-house process engineering capabilities for mRNA drug substance manufacturing.

www.etherna.be

10-MINUTE PRESENTERS​

​​ALERTGY, INC.

Alertgy is a developer of a wearable medical device wristband known as DeepGluco®, which is a truly Non-Invasive Continuous blood Glucose Monitor (NICGM) and alert system to be used by the 422 million diabetics worldwide as well as non-diabetics for real-time blood glucose measurement.

www.alertgy.com/

5-MINUTE PRESENTERS​

Genesis Theranostix

76,000 maternal and 500,000 baby lives can be saved and 7-10 million severe pregnancy complications can be prevented every year with our early pregnancy diagnostics test followed by patient-tailored therapies. The founders – ex-colleagues at NIH – based this unique and best-in-class technology on proprietary patent and know-how utilizing the tools of systems biology and precision medicine.

​www.genesistheranostix.com/